Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 20/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL1183723 | 0.96 | SLC10A2 (0.52) | SLC10A2 | |
| SCHEMBL5762558 | 0.96 | SLC10A2 (0.53) | SLC10A2 | |
| SCHEMBL4790922 | 0.94 | SLC10A2 (0.44) | SLC10A2 | |
| SCHEMBL920147 | 0.90 | SLC10A2 (0.59) | SLC10A2 | |
| Ammonia Solution, Strong SCHEMBL5497725 | 0.88 | SLC10A2 (0.52) | SLC10A2 | |
| SCHEMBL3611683 | 0.86 | SLC10A2 (0.34) | SLC10A2 | |
| SCHEMBL931590 | 0.83 | SLC10A2 (0.36) | SLC10A2 | |
| Ammonia Solution, Strong SCHEMBL5497727 | 0.81 | SLC10A2 (0.54) | SLC10A2 | |
| SCHEMBL1362226 | 0.76 | SLC10A2 (0.72) | SLC10A2 | |
| SCHEMBL932324 | 0.76 | SLC10A2 (0.58) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168039-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-20090005321-A1 | Phenylazetidinone Derivatives | MICROBIA, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | MICROBIA, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1539120-A1 | COMBINATION OF AN IBAT INHIBITOR AND A METAL SALT FOR THE TREATMENT OF DIARRHOEA | Astrazeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004006899-A1 | COMBINATION OF AN IBAT INHIBITOR AND A METAL SALT FOR THE TREATMENT OF DIARRHOEA | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | CYP46A1, CYP7A1, UGT1A1 | SLC10A2 100/4885 |
| US-20100168039-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | CYP46A1, NPC1L1, NPC1 | SLC10A2 48/4885 |
| US-20090005321-A1 | Phenylazetidinone Derivatives | TYR, AAAS, FANCD2 | SLC10A2 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.